TherapeuticsMD Inc (NASDAQ:TXMD) has a bull cheering on back of news the drug maker is resubmitting its NDA to the FDA for vaginal softgel capsule TX-004- an asset that this Wall Street analyst votes has good chances for approval, especially if regulators are involved here. Cantor analyst William Tanner finds that as the company makes its way to garnering the FDA nod in dyspareunia, what reasons do bears have left to cling to aside from “desperation?”
Story Continues
